Prostate cancer
INACTIVE ---Treatment decision-making in castration-resistant prostate cancerScott (58 years old)
Scott, a 58-year-old carpenter, has no major comorbidities. He was diagnosed with multiple bone metastatic PCa:
- CT scan: prostatic enlargement, no sign of visceral metastases
- PSA: 385 ng/ml
- ISUP grade 3 [Gleason score: 4+3]
- Asymptomatic but experiences fatigue
He was treated with ADT + 6 cycles of docetaxel. His PSA at 6 months was 2.1 ng/ml, ALP 31 U/l.
At 24 months post-ADT initiation:
- Increase in PSA to 24 ng/ml in 8 months
- Castrate testosterone level
- Bone scan shows progression of bone metastases
- CT scan shows 1 visceral metastasis (lung)
- Bone pain: requires paracetamol
- ECOG PS: 1
Treatment for mCRPC was started with abiraterone:
- PSA dropped to 4.1 ng/ml
- Bone metastases shrank by 20% (RECIST)
9 months after starting abiraterone:
- PSA rise to 20 ng/ml, ALP to 185 U/l
- Radiographic progression of lymph nodes and lung metastasis
- ECOG PS: 1